Known targets — ChEMBL curated mechanism
CHRM1CHRM2CHRM3CHRM4CHRM5SLC6A2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TERT | O14746 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9442688 | 0.86 | CYP2C9 (0.47) | CYP2C9TERTALDH1A1CTDSP1LMNA | |
| SCHEMBL4757145 | 0.84 | CYP2C9 (0.54) | CYP2C9L3MBTL1ALDH1A1LMNACYP3A4 | |
| SCHEMBL11556453 | 0.78 | CYP2C9 (0.52) | CYP2C9L3MBTL1MEN1KMT2A | |
| SCHEMBL8444430 | 0.77 | CYP2C9 (0.51) | CYP2C9L3MBTL1ALDH1A1LMNACYP3A4 | |
| SCHEMBL4755281 | 0.77 | CYP2C9 (0.46) | CYP2C9L3MBTL1ALDH1A1LMNACYP3A4 | |
| SCHEMBL18954332 | 0.76 | CYP2C9 (0.47) | CYP2C9L3MBTL1TERTALDH1A1CTDSP1 | |
| SCHEMBL28949348 | 0.76 | CYP2C9 (0.47) | CYP2C9L3MBTL1ALDH1A1LMNACYP3A4 | |
| SCHEMBL29903842 | 0.75 | CYP2C9 (0.45) | CYP2C9ALDH1A1LMNACYP3A4PKM | |
| SCHEMBL868812 | 0.74 | HPGD (0.42) | L3MBTL1TERTCTDSP1APOBEC3AAPOBEC3G | |
| SCHEMBL9442692 | 0.74 | ALDH1A1 (0.40) | CYP2C9L3MBTL1ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220265857-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2022-08-25 | — | — | US | disclosed |
| EP-3386484-B1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11285222-B2 | Compositions and methods for delivery of agents | MODERNATX, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200206362-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2020-07-02 | — | — | US | disclosed |
| US-10556018-B2 | Compositions and methods for delivery of agents | ARES CAPITAL CORPORATION, AS AGENT | 2020-02-11 | — | — | US | disclosed |
| US-20190117798-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10207010-B2 | Compositions and methods for delivery of agents | MODERNATX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| EP-3386484-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2017099823-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117798-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | CYP2C9 4726/4885L3MBTL1 274/4885TERT 2401/4885 |
| US-10556018-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | CYP2C9 4726/4885L3MBTL1 274/4885TERT 2401/4885 |
| US-20200206362-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | CYP2C9 4726/4885L3MBTL1 274/4885TERT 2401/4885 |
| US-10207010-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | CYP2C9 4726/4885L3MBTL1 274/4885TERT 2401/4885 |
| US-11285222-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | CYP2C9 4726/4885L3MBTL1 274/4885TERT 2401/4885 |
| US-20220265857-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | CYP2C9 4726/4885L3MBTL1 274/4885TERT 2401/4885 |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | CYP2C9 4726/4885L3MBTL1 274/4885TERT 2401/4885 |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | CYP2C9 4726/4885L3MBTL1 274/4885TERT 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.